4.7 Review

The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy

Journal

NATURE REVIEWS CANCER
Volume 8, Issue 4, Pages 253-267

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/nrc2347

Keywords

-

Categories

Funding

  1. NCI NIH HHS [1R01CA105118-01] Funding Source: Medline
  2. NATIONAL CANCER INSTITUTE [R01CA105118] Funding Source: NIH RePORTER

Ask authors/readers for more resources

sThe cyclin-dependent kinase ( Cdk) inhibitor p27 ( also known as KIP1) regulates cell proliferation, cell motility and apoptosis. Interestingly, the protein can exert both positive and negative functions on these processes. Diverse post-translational modifications determine the physiological role of p27. Phosphorylation regulates p27 binding to and inhibition of cyclin-Cdk complexes, its localization and its ubiquitin-mediated proteolysis. In cancers, p27 is inactivated through impaired synthesis, accelerated degradation and by mislocalization. Moreover, studies in several tumour types indicate that p27 expression levels have both prognostic and therapeutic implications.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available